For over a century, vaccines have been a pillar of medical care. Every vaccine developed to date is based upon the same fundamental principle: by teaching our immune systems to recognize a pathogen and destroy it, we can help protect our bodies from infectious diseases. We are building on this principle to develop vaccines against SARS-CoV-2, the coronavirus that causes COVID-19.
The adjuvanted recombinant protein vaccine candidate. In collaboration with the US BARDA, this booster vaccine candidate uses our recombinant protein manufacturing platform together with GSK’s pandemic adjuvant platform. On December 15th, Sanofi and GSK announced positive preliminary results of a study investigating the safety and immune response with their vaccine candidate as a booster regardless of primary vaccine received (mRNA or adenovirus vector based vaccines).
Sanofi continues its ongoing phase 3 trial of the vaccine following a recommendation from the Data Safety and Monitoring Board (DSMB), an independent data oversight body. The DSMB identified no safety concerns and recommended the trial continue into early 2022 to collect and provide the data necessary for regulatory submissions.
In addition to these clinical trials, recently published preclinical data showed that it has the potential to strongly boost immune responses following vaccination with many of the currently approved vaccines and against a broad range of variants.